カテゴリー： 世界, 医療/バイオ, LP Information

世界の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場予測 2023年-2029年

【英語タイトル】Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC02667）・商品コード：LP23DC02667
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：114
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥549,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥823,500見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,098,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場」は、過去の販売実績から2022年の世界の豚ハイオニューモニエマイコプラズマ不活化ワクチンの総販売量を検討し、2023年から2029年の予測される豚ハイオニューモニエマイコプラズマ不活化ワクチンの販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の豚ハイオニューモニエマイコプラズマ不活化ワクチンの市場規模を掲載し、XXX百万米ドル規模の世界の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場の詳細な分析を提供します。本インサイトレポートは、世界の豚ハイオニューモニエマイコプラズマ不活化ワクチン業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場における各社の独自のポジションをより深く理解するために、豚ハイオニューモニエマイコプラズマ不活化ワクチン製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。豚ハイオニューモニエマイコプラズマ不活化ワクチンの米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。豚ハイオニューモニエマイコプラズマ不活化ワクチンの中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。豚ハイオニューモニエマイコプラズマ不活化ワクチンのヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

豚ハイオニューモニエマイコプラズマ不活化ワクチンの世界主要メーカーとしては、Zoetis Animal Health、 Boehringer-Ingelheim、 Eurovet、 Hipra、 Merck Animal Health、 Ceva Animal Health、 Intervet (AKZO-NOBEL)、 SPAH、 Nanjing Tianbang Biological Technology、 Sichuan Huapai Bio-pharmaceutical、 Guangdong Winsun Bio Pharmaceutical、 Sichuan Yihe Animal Medicine、 Pulike、 Harbin Pharmaceutical Group Bio-Vaccine、 Ringpu、 JiLin ZhengYe Biological Products、 China Animal Husbandry Industryなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では豚ハイオニューモニエマイコプラズマ不活化ワクチン市場をセグメンテーションし、種類別 (点鼻薬、胸部注射、筋肉注射、肺内注射)、用途別 (子豚、成豚)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：点鼻薬、胸部注射、筋肉注射、肺内注射

・用途別区分：子豚、成豚

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場の10年間の市場状況・展望は？
・世界および地域別に見た豚ハイオニューモニエマイコプラズマ不活化ワクチン市場成長の要因は何か？
・豚ハイオニューモニエマイコプラズマ不活化ワクチンの市場機会はエンドマーケットの規模によってどのように変化するのか？
・豚ハイオニューモニエマイコプラズマ不活化ワクチンのタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：豚ハイオニューモニエマイコプラズマ不活化ワクチンの年間販売量2018-2029、地域別現状・将来分析
・豚ハイオニューモニエマイコプラズマ不活化ワクチンの種類別セグメント：点鼻薬、胸部注射、筋肉注射、肺内注射
・豚ハイオニューモニエマイコプラズマ不活化ワクチンの種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・豚ハイオニューモニエマイコプラズマ不活化ワクチンの用途別セグメント：子豚、成豚
・豚ハイオニューモニエマイコプラズマ不活化ワクチンの用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場
・企業別のグローバル豚ハイオニューモニエマイコプラズマ不活化ワクチン市場データ：2018-2023年の年間販売量、市場シェア
・企業別の豚ハイオニューモニエマイコプラズマ不活化ワクチンの年間売上：2018-2023年の売上、市場シェア
・企業別の豚ハイオニューモニエマイコプラズマ不活化ワクチン販売価格
・主要企業の豚ハイオニューモニエマイコプラズマ不活化ワクチン生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

豚ハイオニューモニエマイコプラズマ不活化ワクチンの地域別レビュー
・地域別の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場規模2018-2023：年間販売量、売上
・主要国別の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場規模2018-2023：年間販売量、売上
・南北アメリカの豚ハイオニューモニエマイコプラズマ不活化ワクチン販売の成長
・アジア太平洋の豚ハイオニューモニエマイコプラズマ不活化ワクチン販売の成長
・ヨーロッパの豚ハイオニューモニエマイコプラズマ不活化ワクチン販売の成長
・中東・アフリカの豚ハイオニューモニエマイコプラズマ不活化ワクチン販売の成長

南北アメリカ市場
・南北アメリカの国別の豚ハイオニューモニエマイコプラズマ不活化ワクチン販売量、売上（2018-2023）
・南北アメリカの豚ハイオニューモニエマイコプラズマ不活化ワクチンの種類別販売量
・南北アメリカの豚ハイオニューモニエマイコプラズマ不活化ワクチンの用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の豚ハイオニューモニエマイコプラズマ不活化ワクチン販売量、売上（2018-2023）
・アジア太平洋の豚ハイオニューモニエマイコプラズマ不活化ワクチンの種類別販売量
・アジア太平洋の豚ハイオニューモニエマイコプラズマ不活化ワクチンの用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の豚ハイオニューモニエマイコプラズマ不活化ワクチン販売量、売上（2018-2023）
・ヨーロッパの豚ハイオニューモニエマイコプラズマ不活化ワクチンの種類別販売量
・ヨーロッパの豚ハイオニューモニエマイコプラズマ不活化ワクチンの用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の豚ハイオニューモニエマイコプラズマ不活化ワクチン販売量、売上（2018-2023）
・中東・アフリカの豚ハイオニューモニエマイコプラズマ不活化ワクチンの種類別販売量
・中東・アフリカの豚ハイオニューモニエマイコプラズマ不活化ワクチンの用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・豚ハイオニューモニエマイコプラズマ不活化ワクチンの製造コスト構造分析
・豚ハイオニューモニエマイコプラズマ不活化ワクチンの製造プロセス分析
・豚ハイオニューモニエマイコプラズマ不活化ワクチンの産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・豚ハイオニューモニエマイコプラズマ不活化ワクチンの主要なグローバル販売業者
・豚ハイオニューモニエマイコプラズマ不活化ワクチンの主要なグローバル顧客

地域別の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場予測レビュー
・地域別の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・豚ハイオニューモニエマイコプラズマ不活化ワクチンの種類別市場規模予測
・豚ハイオニューモニエマイコプラズマ不活化ワクチンの用途別市場規模予測

主要企業分析
Zoetis Animal Health、 Boehringer-Ingelheim、 Eurovet、 Hipra、 Merck Animal Health、 Ceva Animal Health、 Intervet (AKZO-NOBEL)、 SPAH、 Nanjing Tianbang Biological Technology、 Sichuan Huapai Bio-pharmaceutical、 Guangdong Winsun Bio Pharmaceutical、 Sichuan Yihe Animal Medicine、 Pulike、 Harbin Pharmaceutical Group Bio-Vaccine、 Ringpu、 JiLin ZhengYe Biological Products、 China Animal Husbandry Industry
・企業情報
・豚ハイオニューモニエマイコプラズマ不活化ワクチン製品
・豚ハイオニューモニエマイコプラズマ不活化ワクチン販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Swine Hyopneumoniae Mycoplasma Inactivated Vaccine players cover Zoetis Animal Health, Boehringer-Ingelheim, Eurovet, Hipra, Merck Animal Health, Ceva Animal Health, Intervet (AKZO-NOBEL), SPAH and Nanjing Tianbang Biological Technology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Swine Hyopneumoniae Mycoplasma Vaccine contains inactivated Mycoplasma hyopneumoniae, which is a light yellow spongy loose mass, which is easy to separate from the bottle wall and quickly dissolves into a uniform suspension after adding diluent. For the prevention of swine mycoplasma pneumonia.
LPI (LP Information)’ newest research report, the “Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Industry Forecast” looks at past sales and reviews total world Swine Hyopneumoniae Mycoplasma Inactivated Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Swine Hyopneumoniae Mycoplasma Inactivated Vaccine sales for 2023 through 2029. With Swine Hyopneumoniae Mycoplasma Inactivated Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Swine Hyopneumoniae Mycoplasma Inactivated Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Swine Hyopneumoniae Mycoplasma Inactivated Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Nasal Spray
Chest Injection
Intramuscular Injection
Intrapulmonary Injection
Segmentation by application
Piglets
Adults Pigs
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Zoetis Animal Health
Boehringer-Ingelheim
Eurovet
Hipra
Merck Animal Health
Ceva Animal Health
Intervet (AKZO-NOBEL)
SPAH
Nanjing Tianbang Biological Technology
Sichuan Huapai Bio-pharmaceutical
Guangdong Winsun Bio Pharmaceutical
Sichuan Yihe Animal Medicine
Pulike
Harbin Pharmaceutical Group Bio-Vaccine
Ringpu
JiLin ZhengYe Biological Products
China Animal Husbandry Industry
Key Questions Addressed in this Report
What is the 10-year outlook for the global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine market?
What factors are driving Swine Hyopneumoniae Mycoplasma Inactivated Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Swine Hyopneumoniae Mycoplasma Inactivated Vaccine market opportunities vary by end market size?
How does Swine Hyopneumoniae Mycoplasma Inactivated Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Segment by Type
2.2.1 Nasal Spray
2.2.2 Chest Injection
2.2.3 Intramuscular Injection
2.2.4 Intrapulmonary Injection
2.3 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type
2.3.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Price by Type (2018-2023)
2.4 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Segment by Application
2.4.1 Piglets
2.4.2 Adults Pigs
2.5 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application
2.5.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Price by Application (2018-2023)
3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Company
3.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Breakdown Data by Company
3.1.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Company (2018-2023)
3.2.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Price by Company
3.4 Key Manufacturers Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Location Distribution
3.4.2 Players Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Geographic Region
4.1 World Historic Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Growth
4.4 APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Growth
4.5 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Growth
4.6 Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Growth
5 Americas
5.1 Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country
5.1.1 Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2018-2023)
5.1.2 Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2018-2023)
5.2 Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type
5.3 Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region
6.1.1 APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region (2018-2023)
6.1.2 APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Region (2018-2023)
6.2 APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type
6.3 APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Country
7.1.1 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2018-2023)
7.1.2 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2018-2023)
7.2 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type
7.3 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Country
8.1.1 Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type
8.3 Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine
10.3 Manufacturing Process Analysis of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine
10.4 Industry Chain Structure of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Distributors
11.3 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Customer
12 World Forecast Review for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Geographic Region
12.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size Forecast by Region
12.1.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Forecast by Region (2024-2029)
12.1.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Forecast by Type
12.7 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Forecast by Application
13 Key Players Analysis
13.1 Zoetis Animal Health
13.1.1 Zoetis Animal Health Company Information
13.1.2 Zoetis Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.1.3 Zoetis Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Zoetis Animal Health Main Business Overview
13.1.5 Zoetis Animal Health Latest Developments
13.2 Boehringer-Ingelheim
13.2.1 Boehringer-Ingelheim Company Information
13.2.2 Boehringer-Ingelheim Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.2.3 Boehringer-Ingelheim Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Boehringer-Ingelheim Main Business Overview
13.2.5 Boehringer-Ingelheim Latest Developments
13.3 Eurovet
13.3.1 Eurovet Company Information
13.3.2 Eurovet Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.3.3 Eurovet Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Eurovet Main Business Overview
13.3.5 Eurovet Latest Developments
13.4 Hipra
13.4.1 Hipra Company Information
13.4.2 Hipra Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.4.3 Hipra Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Hipra Main Business Overview
13.4.5 Hipra Latest Developments
13.5 Merck Animal Health
13.5.1 Merck Animal Health Company Information
13.5.2 Merck Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.5.3 Merck Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Merck Animal Health Main Business Overview
13.5.5 Merck Animal Health Latest Developments
13.6 Ceva Animal Health
13.6.1 Ceva Animal Health Company Information
13.6.2 Ceva Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.6.3 Ceva Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Ceva Animal Health Main Business Overview
13.6.5 Ceva Animal Health Latest Developments
13.7 Intervet (AKZO-NOBEL)
13.7.1 Intervet (AKZO-NOBEL) Company Information
13.7.2 Intervet (AKZO-NOBEL) Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.7.3 Intervet (AKZO-NOBEL) Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Intervet (AKZO-NOBEL) Main Business Overview
13.7.5 Intervet (AKZO-NOBEL) Latest Developments
13.8 SPAH
13.8.1 SPAH Company Information
13.8.2 SPAH Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.8.3 SPAH Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 SPAH Main Business Overview
13.8.5 SPAH Latest Developments
13.9 Nanjing Tianbang Biological Technology
13.9.1 Nanjing Tianbang Biological Technology Company Information
13.9.2 Nanjing Tianbang Biological Technology Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.9.3 Nanjing Tianbang Biological Technology Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Nanjing Tianbang Biological Technology Main Business Overview
13.9.5 Nanjing Tianbang Biological Technology Latest Developments
13.10 Sichuan Huapai Bio-pharmaceutical
13.10.1 Sichuan Huapai Bio-pharmaceutical Company Information
13.10.2 Sichuan Huapai Bio-pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.10.3 Sichuan Huapai Bio-pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Sichuan Huapai Bio-pharmaceutical Main Business Overview
13.10.5 Sichuan Huapai Bio-pharmaceutical Latest Developments
13.11 Guangdong Winsun Bio Pharmaceutical
13.11.1 Guangdong Winsun Bio Pharmaceutical Company Information
13.11.2 Guangdong Winsun Bio Pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.11.3 Guangdong Winsun Bio Pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Guangdong Winsun Bio Pharmaceutical Main Business Overview
13.11.5 Guangdong Winsun Bio Pharmaceutical Latest Developments
13.12 Sichuan Yihe Animal Medicine
13.12.1 Sichuan Yihe Animal Medicine Company Information
13.12.2 Sichuan Yihe Animal Medicine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.12.3 Sichuan Yihe Animal Medicine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Sichuan Yihe Animal Medicine Main Business Overview
13.12.5 Sichuan Yihe Animal Medicine Latest Developments
13.13 Pulike
13.13.1 Pulike Company Information
13.13.2 Pulike Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.13.3 Pulike Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Pulike Main Business Overview
13.13.5 Pulike Latest Developments
13.14 Harbin Pharmaceutical Group Bio-Vaccine
13.14.1 Harbin Pharmaceutical Group Bio-Vaccine Company Information
13.14.2 Harbin Pharmaceutical Group Bio-Vaccine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.14.3 Harbin Pharmaceutical Group Bio-Vaccine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Harbin Pharmaceutical Group Bio-Vaccine Main Business Overview
13.14.5 Harbin Pharmaceutical Group Bio-Vaccine Latest Developments
13.15 Ringpu
13.15.1 Ringpu Company Information
13.15.2 Ringpu Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.15.3 Ringpu Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Ringpu Main Business Overview
13.15.5 Ringpu Latest Developments
13.16 JiLin ZhengYe Biological Products
13.16.1 JiLin ZhengYe Biological Products Company Information
13.16.2 JiLin ZhengYe Biological Products Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.16.3 JiLin ZhengYe Biological Products Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 JiLin ZhengYe Biological Products Main Business Overview
13.16.5 JiLin ZhengYe Biological Products Latest Developments
13.17 China Animal Husbandry Industry
13.17.1 China Animal Husbandry Industry Company Information
13.17.2 China Animal Husbandry Industry Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
13.17.3 China Animal Husbandry Industry Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 China Animal Husbandry Industry Main Business Overview
13.17.5 China Animal Husbandry Industry Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Nasal Spray
Table 4. Major Players of Chest Injection
Table 5. Major Players of Intramuscular Injection
Table 6. Major Players of Intrapulmonary Injection
Table 7. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2018-2023) & (K Doses)
Table 8. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2018-2023)
Table 9. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Type (2018-2023) & ($ million)
Table 10. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Type (2018-2023)
Table 11. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Price by Type (2018-2023) & (US$/Dose)
Table 12. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2018-2023) & (K Doses)
Table 13. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Application (2018-2023)
Table 14. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Application (2018-2023)
Table 15. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Application (2018-2023)
Table 16. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Price by Application (2018-2023) & (US$/Dose)
Table 17. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Company (2018-2023) & (K Doses)
Table 18. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Company (2018-2023)
Table 19. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Company (2018-2023)
Table 21. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Price by Company (2018-2023) & (US$/Dose)
Table 22. Key Manufacturers Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Producing Area Distribution and Sales Area
Table 23. Players Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Products Offered
Table 24. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Geographic Region (2018-2023) & (K Doses)
Table 28. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share Geographic Region (2018-2023)
Table 29. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country/Region (2018-2023) & (K Doses)
Table 32. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country/Region (2018-2023)
Table 33. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2018-2023) & (K Doses)
Table 36. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country (2018-2023)
Table 37. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country (2018-2023)
Table 39. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2018-2023) & (K Doses)
Table 40. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2018-2023) & (K Doses)
Table 41. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region (2018-2023) & (K Doses)
Table 42. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Region (2018-2023)
Table 43. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Region (2018-2023)
Table 45. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2018-2023) & (K Doses)
Table 46. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2018-2023) & (K Doses)
Table 47. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2018-2023) & (K Doses)
Table 48. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country (2018-2023)
Table 49. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country (2018-2023)
Table 51. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2018-2023) & (K Doses)
Table 52. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2018-2023) & (K Doses)
Table 53. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2018-2023) & (K Doses)
Table 54. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2018-2023) & (K Doses)
Table 58. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2018-2023) & (K Doses)
Table 59. Key Market Drivers & Growth Opportunities of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine
Table 60. Key Market Challenges & Risks of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine
Table 61. Key Industry Trends of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine
Table 62. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Distributors List
Table 65. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Customer List
Table 66. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Forecast by Region (2024-2029) & (K Doses)
Table 67. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Forecast by Country (2024-2029) & (K Doses)
Table 69. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Forecast by Region (2024-2029) & (K Doses)
Table 71. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Forecast by Country (2024-2029) & (K Doses)
Table 73. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Forecast by Country (2024-2029) & (K Doses)
Table 75. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Forecast by Type (2024-2029) & (K Doses)
Table 77. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Forecast by Application (2024-2029) & (K Doses)
Table 79. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Zoetis Animal Health Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 81. Zoetis Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 82. Zoetis Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 83. Zoetis Animal Health Main Business
Table 84. Zoetis Animal Health Latest Developments
Table 85. Boehringer-Ingelheim Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 86. Boehringer-Ingelheim Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 87. Boehringer-Ingelheim Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 88. Boehringer-Ingelheim Main Business
Table 89. Boehringer-Ingelheim Latest Developments
Table 90. Eurovet Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 91. Eurovet Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 92. Eurovet Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 93. Eurovet Main Business
Table 94. Eurovet Latest Developments
Table 95. Hipra Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 96. Hipra Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 97. Hipra Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 98. Hipra Main Business
Table 99. Hipra Latest Developments
Table 100. Merck Animal Health Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 101. Merck Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 102. Merck Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 103. Merck Animal Health Main Business
Table 104. Merck Animal Health Latest Developments
Table 105. Ceva Animal Health Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 106. Ceva Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 107. Ceva Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 108. Ceva Animal Health Main Business
Table 109. Ceva Animal Health Latest Developments
Table 110. Intervet (AKZO-NOBEL) Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 111. Intervet (AKZO-NOBEL) Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 112. Intervet (AKZO-NOBEL) Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 113. Intervet (AKZO-NOBEL) Main Business
Table 114. Intervet (AKZO-NOBEL) Latest Developments
Table 115. SPAH Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 116. SPAH Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 117. SPAH Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 118. SPAH Main Business
Table 119. SPAH Latest Developments
Table 120. Nanjing Tianbang Biological Technology Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 121. Nanjing Tianbang Biological Technology Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 122. Nanjing Tianbang Biological Technology Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 123. Nanjing Tianbang Biological Technology Main Business
Table 124. Nanjing Tianbang Biological Technology Latest Developments
Table 125. Sichuan Huapai Bio-pharmaceutical Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 126. Sichuan Huapai Bio-pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 127. Sichuan Huapai Bio-pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 128. Sichuan Huapai Bio-pharmaceutical Main Business
Table 129. Sichuan Huapai Bio-pharmaceutical Latest Developments
Table 130. Guangdong Winsun Bio Pharmaceutical Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 131. Guangdong Winsun Bio Pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 132. Guangdong Winsun Bio Pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 133. Guangdong Winsun Bio Pharmaceutical Main Business
Table 134. Guangdong Winsun Bio Pharmaceutical Latest Developments
Table 135. Sichuan Yihe Animal Medicine Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 136. Sichuan Yihe Animal Medicine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 137. Sichuan Yihe Animal Medicine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 138. Sichuan Yihe Animal Medicine Main Business
Table 139. Sichuan Yihe Animal Medicine Latest Developments
Table 140. Pulike Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 141. Pulike Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 142. Pulike Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 143. Pulike Main Business
Table 144. Pulike Latest Developments
Table 145. Harbin Pharmaceutical Group Bio-Vaccine Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 146. Harbin Pharmaceutical Group Bio-Vaccine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 147. Harbin Pharmaceutical Group Bio-Vaccine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 148. Harbin Pharmaceutical Group Bio-Vaccine Main Business
Table 149. Harbin Pharmaceutical Group Bio-Vaccine Latest Developments
Table 150. Ringpu Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 151. Ringpu Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 152. Ringpu Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 153. Ringpu Main Business
Table 154. Ringpu Latest Developments
Table 155. JiLin ZhengYe Biological Products Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 156. JiLin ZhengYe Biological Products Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 157. JiLin ZhengYe Biological Products Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 158. JiLin ZhengYe Biological Products Main Business
Table 159. JiLin ZhengYe Biological Products Latest Developments
Table 160. China Animal Husbandry Industry Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 161. China Animal Husbandry Industry Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 162. China Animal Husbandry Industry Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2018-2023)
Table 163. China Animal Husbandry Industry Main Business
Table 164. China Animal Husbandry Industry Latest Developments
List of Figures
Figure 1. Picture of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine
Figure 2. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Growth Rate 2018-2029 (K Doses)
Figure 7. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Nasal Spray
Figure 10. Product Picture of Chest Injection
Figure 11. Product Picture of Intramuscular Injection
Figure 12. Product Picture of Intrapulmonary Injection
Figure 13. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type in 2022
Figure 14. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Type (2018-2023)
Figure 15. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Consumed in Piglets
Figure 16. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market: Piglets (2018-2023) & (K Doses)
Figure 17. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Consumed in Adults Pigs
Figure 18. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market: Adults Pigs (2018-2023) & (K Doses)
Figure 19. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Application (2022)
Figure 20. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Application in 2022
Figure 21. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market by Company in 2022 (K Doses)
Figure 22. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Company in 2022
Figure 23. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Company in 2022
Figure 25. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales 2018-2023 (K Doses)
Figure 28. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue 2018-2023 ($ Millions)
Figure 29. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales 2018-2023 (K Doses)
Figure 30. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue 2018-2023 ($ Millions)
Figure 31. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales 2018-2023 (K Doses)
Figure 32. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales 2018-2023 (K Doses)
Figure 34. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue 2018-2023 ($ Millions)
Figure 35. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country in 2022
Figure 36. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country in 2022
Figure 37. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2018-2023)
Figure 38. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Application (2018-2023)
Figure 39. United States Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Region in 2022
Figure 44. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Regions in 2022
Figure 45. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2018-2023)
Figure 46. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Application (2018-2023)
Figure 47. China Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country in 2022
Figure 55. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country in 2022
Figure 56. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2018-2023)
Figure 57. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Application (2018-2023)
Figure 58. Germany Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Application (2018-2023)
Figure 67. Egypt Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine in 2022
Figure 73. Manufacturing Process Analysis of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine
Figure 74. Industry Chain Structure of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine
Figure 75. Channels of Distribution
Figure 76. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Forecast by Region (2024-2029)
Figure 77. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場予測 2023年-2029年] (コード：LP23DC02667)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の豚ハイオニューモニエマイコプラズマ不活化ワクチン市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の豚流行性脳炎不活化ワクチン市場予測 2023年-2029年
  • 世界の豚伝染性胃腸炎・豚流行性下痢・豚ロタウイルスワクチン市場予測 2023年-2029年
  • 世界の再集合体鳥インフルエンザウイルスワクチン市場予測 2023年-2029年
  • 世界の動物用ワクチン市場予測 2023年-2029年
  • 世界の反芻動物ワクチン市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆